Case Reports: Withdrawal Phenomenon With the Antiandrogen Casodex

[1]  P. Carroll,et al.  Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. , 1994, Urology.

[2]  M. Koutsilieris,et al.  Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. , 1993, The Journal of urology.

[3]  H. Scher,et al.  Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  H. Scher,et al.  Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. , 1993, The Journal of urology.

[5]  J. Veldscholte,et al.  Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. , 1992, Biochemistry.

[6]  G. Kennealey,et al.  Use of the nonsteroidal anti-androgen Casodex in advanced prostatic carcinoma. , 1991, The Urologic clinics of North America.

[7]  P. Goodman,et al.  A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. , 1989, The New England journal of medicine.

[8]  J. Aisner,et al.  Tamoxifen withdrawal response. Report of a case. , 1989, Archives of internal medicine.

[9]  M. Chen,et al.  Aberrant response in vitro of hormone‐responsive prostate cancer cells to antiandrogens , 1989, The Prostate.

[10]  F. Labrie,et al.  Low androgen levels induce the development of androgen-hypersensitive cell clones in Shionogi mouse mammary carcinoma cells in culture. , 1988, Journal of the National Cancer Institute.

[11]  P. Band,et al.  Tamoxifen-induced tumor stimulation and withdrawal response. , 1979, Cancer treatment reports.